profit from every $100 of sales.
$0$100
Boundless Bio
$2.46+0.00% today
+100.0% in 1 year
1-year low $1.051-year high $3.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Boundless Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$58.2 million of profit last year.
SalesProfit
Boundless Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Boundless Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Boundless Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -46 | -55 | -73 | -64 | |
| -46 | -54 | -72 | -62 | |
| -46 | -49 | -65 | -58 | |
| -3.28 | -2.22 | -3.85 | -2.60 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 77 | 130 | 206 | 157 |
| Cash | 11 | 24 | 27 | 18 |
| Total debt | 5 | 2 | 48 | 49 |
| Total liabilities | 159 | 257 | 56 | 58 |
| -82 | -127 | 151 | 99 | |
| 14 | 22 | 17 | 22 | |
| – | – | -29.2% | -34.0% | |
| 56.2% | 38.9% | -43.4% | -59.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -40 | -47 | -61 | -47 | |
| 1 | 1 | 3 | 1 | |
| -41 | -47 | -63 | -47 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 3 | 8 | 6 |
Valuation
- –
- –
- –
- 0.4×
- –
- –
- –
- -81.3%
- -100.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -45.1%
- 18.8%
- -53.6%
- -39.7%
- -46.2%
- –
Growth
- –
- –
- +25.5%
- –
- +0.1%
Financial health
- -0.5×
- 0.56
- 34.3%
- –
- 9.87
- 9.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 952
Bottom 20%of 883
Bottom 1%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.60 | -0.51 | −17.6% |
| Mar 9, 2026 | -0.58 | -0.44 | −31.8% |
| Nov 5, 2025 | -0.62 | -0.53 | −17.0% |
| Aug 5, 2025 | -0.70 | -0.75 | +6.7% |
| May 9, 2025 | -0.71 | -0.68 | −4.4% |
| Mar 27, 2025 | -0.74 | -0.74 | +0.0% |
| Nov 7, 2024 | -0.74 | -0.76 | +2.6% |
| Aug 12, 2024 | -0.77 | -0.78 | +1.3% |
News
J.P. Morgan Just Made a Bold Prediction About Bitcoin. Should You Buy It?Yahoo Finance · Nov 1, 2026Amazon’s stock drops — even in the face of a bold new cloud forecastMarketWatch · Oct 30, 2026Retail investors are aggressively piling into this bold contrarian bet through one ETF.MarketWatch · Oct 1, 2026Bill Gates makes bold predictions on the future of humanity and AIYahoo Finance · Sep 29, 2026Cathie Wood's Ark Has Delivered Just a 13.8% Annualized Return Since 2014, Roughly Matching the S&P 500. Should You Trust Her Bold Predictions for 2030?Yahoo Finance · Sep 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
77Pass
Philip Fisher
46No pass
Peter Lynch
53No pass
Joel Greenblatt
2No pass
Charlie Munger
40No pass
Terry Smith
39No pass
Questions about Boundless Bio
Is Boundless Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Boundless Bio AI analysis
What does Boundless Bio do?
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. It is in Biotechnology.
Does Boundless Bio pay a dividend?
No. Boundless Bio does not pay a dividend at the moment.
Is Boundless Bio stock halal?
No. Boundless Bio does not pass our halal screen: its debt is 84% of its market value, at or above the 33% limit. How we check
How has Boundless Bio stock done over the past year?
Up 100.0% over the past twelve months, to $2.46. It traded between $1.05 and $3.00 and is 18.0% below its high.
Who are Boundless Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Boundless Bio's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.